Annika E. Michelsen

4.8k total citations · 2 hit papers
75 papers, 3.3k citations indexed

About

Annika E. Michelsen is a scholar working on Immunology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Annika E. Michelsen has authored 75 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 18 papers in Cardiology and Cardiovascular Medicine and 17 papers in Surgery. Recurrent topics in Annika E. Michelsen's work include Atherosclerosis and Cardiovascular Diseases (15 papers), Lipoproteins and Cardiovascular Health (6 papers) and Cardiac Fibrosis and Remodeling (6 papers). Annika E. Michelsen is often cited by papers focused on Atherosclerosis and Cardiovascular Diseases (15 papers), Lipoproteins and Cardiovascular Health (6 papers) and Cardiac Fibrosis and Remodeling (6 papers). Annika E. Michelsen collaborates with scholars based in Norway, United States and Sweden. Annika E. Michelsen's co-authors include Thor Ueland, Fridtjof Lund‐Johansen, Pål Aukrust, Maria Therese Ahlén, Pål André Holme, Anne Hege Aamodt, Nina Haagenrud Schultz, Thor Håkon Skattør, Markus Wiedmann and Geir E. Tjønnfjord and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Immunology.

In The Last Decade

Annika E. Michelsen

73 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

2021 969 citations Annika E. Michelsen, Fridtjof Lund‐Johansen et al. profile →
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial

2016 288 citations Ola Kleveland, Thor Ueland et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annika E. Michelsen Norway	28	996	740	701	639	604	75	3.3k
Philipp Kümpers Germany	34	463 0.5×	463 0.6×	932 1.3×	846 1.3×	819 1.4×	120	3.5k
Georg Endler Austria	34	530 0.5×	507 0.7×	616 0.9×	830 1.3×	902 1.5×	109	3.8k
LeRoy E. Rabbani United States	29	1.1k 1.1×	324 0.4×	421 0.6×	331 0.5×	1.1k 1.9×	110	3.4k
Jon T. Giles United States	45	578 0.6×	1.5k 2.0×	877 1.3×	787 1.2×	1.1k 1.8×	154	6.6k
David Taube United Kingdom	38	1.3k 1.3×	558 0.8×	318 0.5×	494 0.8×	233 0.4×	151	4.5k
Gülali Aktaş Türkiye	36	505 0.5×	267 0.4×	395 0.6×	1.2k 1.9×	508 0.8×	161	3.7k
Pasquale Ambrosino Italy	31	495 0.5×	301 0.4×	218 0.3×	398 0.6×	694 1.1×	131	2.8k
Gerard F. Curley Ireland	33	1.7k 1.7×	282 0.4×	503 0.7×	303 0.5×	309 0.5×	84	4.1k
Kuang‐Hui Yu Taiwan	33	875 0.9×	392 0.5×	493 0.7×	802 1.3×	292 0.5×	122	3.5k
Daniel Chappell Germany	37	2.3k 2.3×	218 0.3×	307 0.4×	1.2k 1.9×	1.4k 2.3×	105	5.7k

Countries citing papers authored by Annika E. Michelsen

Since Specialization

Citations

This map shows the geographic impact of Annika E. Michelsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annika E. Michelsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annika E. Michelsen more than expected).

Fields of papers citing papers by Annika E. Michelsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annika E. Michelsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annika E. Michelsen. The network helps show where Annika E. Michelsen may publish in the future.

Co-authorship network of co-authors of Annika E. Michelsen

This figure shows the co-authorship network connecting the top 25 collaborators of Annika E. Michelsen. A scholar is included among the top collaborators of Annika E. Michelsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annika E. Michelsen. Annika E. Michelsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thorsby, Per Medbøe, Lisa E. Hauger, Kristina H. Haugaa, et al.. (2024). Elevated interleukin 8 and matrix metalloproteinase 9 levels are associated with myocardial pathology in users of anabolic-androgenic steroids. European Journal of Preventive Cardiology. 31(12). 1469–1476. 3 indexed citations

Latysheva, Nadezhda, Annika E. Michelsen, Thor Ueland, et al.. (2023). Complement factors B, D, C3bBbP and risk of future venous thromboembolism. Clinical Immunology. 249. 109278–109278. 2 indexed citations

Einvik, Gunnar, Truls Michael Leegaard, Trygve Tjade, et al.. (2023). Prevalence and Characteristics Associated With Post–COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults. JAMA Network Open. 6(3). e235763–e235763. 59 indexed citations

Simeone, Paola, Romina Tripaldi, Annika E. Michelsen, et al.. (2022). Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss. Cardiovascular Diabetology. 21(1). 36–36. 10 indexed citations

Holt, Margrethe Flesvig, Annika E. Michelsen, Mona Skjelland, et al.. (2022). Markers of extracellular matrix remodeling and systemic inflammation in patients with heritable thoracic aortic diseases. Frontiers in Cardiovascular Medicine. 9. 1073069–1073069. 7 indexed citations

Holt, Margrethe Flesvig, Annika E. Michelsen, Elisabeth Bjørkelund, et al.. (2021). The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure. Frontiers in Immunology. 12. 800978–800978. 5 indexed citations

Ueland, Thor, Axel Åkerblom, Tatevik Ghukasyan Lakic, et al.. (2019). ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis. 293. 35–41. 4 indexed citations

Ueland, Thor, Annika E. Michelsen, Judith Krey Ludviksen, et al.. (2019). Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis. The Journal of Immunology. 203(7). 1973–1980. 8 indexed citations

Lekva, Tove, Kristin Godang, Annika E. Michelsen, et al.. (2018). Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation. Scientific Reports. 8(1). 13392–13392. 22 indexed citations

10.

Ueland, Thor, Ola Kleveland, Annika E. Michelsen, et al.. (2018). Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. International Journal of Cardiology. 274. 348–350. 10 indexed citations

11.

Abraityte, Aurelija, Leif Erik Vinge, Erik T. Askevold, et al.. (2017). Wnt5a is elevated in heart failure and affects cardiac fibroblast function. Journal of Molecular Medicine. 95(7). 767–777. 57 indexed citations

12.

Hoseth, Eva, Thor Ueland, Ingrid Dieset, et al.. (2016). A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue. Schizophrenia Bulletin. 43(4). sbw183–sbw183. 63 indexed citations

13.

Laugsand, Lars Erik, Bjørn Olav Åsvold, Lars J. Vatten, et al.. (2016). Circulating PCSK9 and Risk of Myocardial Infarction. JACC Basic to Translational Science. 1(7). 568–575. 22 indexed citations

14.

Laugsand, Lars Erik, Bjørn Olav Åsvold, Lars J. Vatten, et al.. (2015). Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway. Atherosclerosis. 244. 188–194. 18 indexed citations

15.

Røsjø, Egil, Kjell‐Morten Myhr, Kristin I. Løken-Amsrud, et al.. (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 280. 21–28. 14 indexed citations

16.

Halvorsen, Bente, Tuva B. Dahl, Annika E. Michelsen, et al.. (2014). Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells. Cardiovascular Research. 102(1). 148–156. 32 indexed citations

17.

Wium, Cecilie, Erlend T. Aasheim, Thor Ueland, et al.. (2013). Differences in insulin sensitivity, lipid metabolism and inflammation between young adult Pakistani and Norwegian patients with type 2 diabetes: a cross sectional study. BMC Endocrine Disorders. 13(1). 49–49. 4 indexed citations

18.

Halvorsen, Bente, Isabelle Daissormont, Trine Ranheim, et al.. (2012). Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis – Potential role in plaque stabilization. Atherosclerosis. 224(1). 266–273. 30 indexed citations

19.

Aukrust, Pål, Bente Halvorsen, Thor Ueland, et al.. (2010). Activated platelets and atherosclerosis. Expert Review of Cardiovascular Therapy. 8(9). 1297–1307. 46 indexed citations

20.

Michelsen, Annika E., Ragnhild Wergeland, Oddvar Stokke, & Frank Brosstad. (2005). Development of a time-resolved immunofluorometric assay for quantifying platelet-derived microparticles in human plasma. Thrombosis Research. 117(6). 705–711. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact